Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand ...
Read more
Tag: novo nordisk
Heartseed and Novo Nordisk to collaborate for stem cell-based therapy for heart failure
Heartseed Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive worldwide ...
Read more
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US ...
Read more
Ziltivekimab of Novo Nordisk shows positive Phase II results in atherosclerosis
Novo Nordisk today presented results from RESCUE, a phase 2 randomised, double-blind, placebo controlled clinical trial ...
Read more
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Novo Nordisk announced the decision to enter phase 3a development in obesity with oral semaglutide 50 ...
Read moreSaxenda® recommended for approval by European Medicines Agency
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the ...
Read moreAdults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme demonstrated weight ...
Read moreNovo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal ...
Read more